Bioglan Pharmaceuticals, the UK biotechnology business, has scuppered a potential attempt by Goldman Sachs to rescue it by going into administration.

Earlier on Wednesday it was believed that Goldman Sachs, the company's adviser, had a week to find a buyer for all or part of Bioglan's business, after the company's lender - Bank of Scotland - declined to offer emergency funding.